Immune Design (IMDZ) Issues Positive Update from Ongoing CMB305 and G100 Phase 1s
Tweet Send to a Friend
Immune Design (Nasdaq: IMDZ) reported positive topline data from three ongoing Phase 1 oncology studies that support continued development of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
